Scarica l'app Stockscreener
1.59
3.92%
0.06
Dopo l'orario di chiusura:
1.55
-0.04
-2.52%
Precedente Chiudi:
$1.53
Aprire:
$1.53
Volume 24 ore:
36,914
Relative Volume:
0.15
Capitalizzazione di mercato:
$65.38M
Reddito:
$1.88M
Utile/perdita netta:
$-15.57M
Rapporto P/E:
-3.975
EPS:
-0.4
Flusso di cassa netto:
$-50.09M
1 W Prestazione:
-2.45%
1M Prestazione:
-19.70%
6M Prestazione:
-28.05%
1 anno Prestazione:
-2.45%
Intervallo 1D:
$1.52
$1.65
Intervallo di 1 settimana:
$1.38
$1.74
Portata 52W:
$0.98
$3.44
Beyondspring Inc Stock (BYSI) Company Profile
Nome
Beyondspring Inc
Settore
Industria
Telefono
646-528-4184
Indirizzo
100 CAMPUS DRIVE, WEST SIDE, 4TH FLOOR, FLORHAM PARK, NY
Confronta BYSI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BYSI
Beyondspring Inc
|
1.59 | 62.92M | 1.88M | -15.57M | -50.09M | -0.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Beyondspring Inc Stock (BYSI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-12-02 | Downgrade | BofA Securities | Buy → Underperform |
| 2021-12-02 | Downgrade | Jefferies | Buy → Hold |
| 2021-12-01 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2021-12-01 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2021-09-09 | Iniziato | Robert W. Baird | Outperform |
| 2021-08-04 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2021-04-05 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2021-01-11 | Iniziato | BofA Securities | Buy |
| 2020-12-29 | Iniziato | Evercore ISI | Outperform |
| 2020-02-07 | Iniziato | Jefferies | Buy |
| 2020-01-10 | Iniziato | Nomura | Buy |
| 2019-12-03 | Iniziato | William Blair | Outperform |
| 2019-07-10 | Reiterato | H.C. Wainwright | Buy |
| 2019-04-30 | Downgrade | Maxim Group | Buy → Hold |
| 2018-10-25 | Reiterato | Maxim Group | Buy |
Mostra tutto
Beyondspring Inc Borsa (BYSI) Ultime notizie
Can BeyondSpring Inc. stock maintain operating marginsGlobal Markets & Momentum Based Trading Ideas - ulpravda.ru
Critical Review: Cyclerion Therapeutics (NASDAQ:CYCN) & BeyondSpring (NASDAQ:BYSI) - Defense World
Breakout Zone: How BeyondSpring Inc stock compares to market leaders2025 EndofYear Setup & Short-Term Trading Alerts - moha.gov.vn
Why BeyondSpring Inc. stock could benefit from AI revolutionVolatility Index Analysis & Free Significant Capital Appreciation - bollywoodhelpline.com
S P Trends: Does BeyondSpring Inc stock trade at a discount to peersMarket Movement Recap & Precise Swing Trade Alerts - moha.gov.vn
BeyondSpring Inc. (NASDAQ:BYSI) Sees Large Increase in Short Interest - MarketBeat
BeyondSpring (NASDAQ:BYSI) Shares Down 4.2% – Should You Sell? - Defense World
BeyondSpring (NASDAQ:BYSI) Trading Down 4.2%Should You Sell? - MarketBeat
Why ZIM Integrated Shipping Services Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket - Sahm
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Krystal Biotech (NASDAQ:KRYS) and BeyondSpring (NASDAQ:BYSI) Critical Survey - Defense World
Will BeyondSpring Inc. stock benefit from infrastructure spendingJuly 2025 Trade Ideas & Consistent Growth Equity Picks - Улправда
Can BeyondSpring Inc. stock weather global recessionJuly 2025 Breakouts & Weekly Return Optimization Alerts - Улправда
Will BeyondSpring Inc. stock benefit from sector rotationJuly 2025 Macro Moves & Breakout Confirmation Alerts - DonanımHaber
Will BeyondSpring Inc. stock benefit from AI adoptionMarket Weekly Review & Weekly Chart Analysis and Guides - Улправда
Pharma News: Will BeyondSpring Inc. stock outperform tech sector in 2025Quarterly Trade Summary & Low Risk Investment Opportunities - moha.gov.vn
Beyondspring Delays Second Closings of Share Sale - TipRanks
BeyondSpring Inc. Announces Preferred Share Purchase Agreement - TradingView — Track All Markets
BeyondSpring (NASDAQ: BYSI) now expects SEED share Second Closings in 1H 2026 - Stock Titan
BYSI: Recent Business Developments Shape Market Outlook - StocksToTrade
BeyondSpring Inc. Stock Shows Upward Spike As Earnings Report Uncovers Surprises - StocksToTrade
BeyondSpring Stock Faces Challenges Amid Recent Market Dynamics - timothysykes.com
BeyondSpring Inc. Faces Financial Pressure in the Pharmaceutical Market - timothysykes.com
BYSI Stock Shows Turbulence Amid Financial Uncertainty - StocksToTrade
BYSI Stock Volatility Amidst Strategic Developments and Market Shifts - StocksToTrade
BeyondSpring presents phase 3 DUBLIN-3 data at ESMO Asia Congress - MSN
BYSI’s Stock Roller Coaster: What Happens Next? - StocksToTrade
BeyondSpring Inc.’s Market Shift: Analyzing Financial Trends and Price Movements - timothysykes.com
BeyondSpring’s Stock Gains Steam Amid Market Developments - timothysykes.com
BeyondSpring Inc. (BYSI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
BeyondSpring (BYSI) Stock :Surges 5% as New Plinabulin Data Strengthens Case for Global NSCLC Registration Path - CoinCentral
BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 - marketscreener.com
BYSI: BeyondSpring's Plinabulin Shows Promising Results in Phase 3 Trial - GuruFocus
BeyondSpring stock rises after positive Asian subset data from lung cancer trial - Investing.com Nigeria
BeyondSpring stock rises after positive Asian subset data from lung cancer trial By Investing.com - Investing.com South Africa
BeyondSpring reports positive Asian subset data for lung cancer drug By Investing.com - Investing.com Canada
BeyondSpring reports positive Asian subset data for lung cancer drug - Investing.com
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path - GlobeNewswire
BeyondSpring’s Plinabulin combination shows survival benefit in NSCLC - TipRanks
BeyondSpring (BYSI) Reports Promising Results for Plinabulin in Lung Cancer Study - GuruFocus
BeyondSpring Announces Positive Phase 3 DUBLIN-3 Results for Plinabulin in NSCLC Patients Post Anti-PD-(L)1 Therapy and Plans for Global DUBLIN-4 Trial - Quiver Quantitative
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for Non-squamous EGFR WT NSCLC and a Reduction in Brain Metastasis Compared to Docetaxel at NACLC 2025 - marketscreener.com
BeyondSpring (NASDAQ: BYSI) DUBLIN-3 finds 15.8-month OS, fewer brain mets in NSCLC - Stock Titan
Why 22nd Century Group Inc stock could benefit from AI revolutionTrade Ideas & Accurate Buy Signal Notifications - moha.gov.vn
Beyondspring Inc Azioni (BYSI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.80%
4.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):